Clinical Stage Pipeline Endurance Bio centers on oral small molecules T-168 and T-621, with T-168 in Phase II for neurodegenerative and metabolic diseases and T-621 in IND enabling studies, creating opportunities for licensing, co development, or strategic partnerships across CNS and metabolic indications.

Parkinson Collaboration T-168 has been selected for the Neuro-SysMed Parkinson's disease SLEIPNIR trial with funding from Cure Parkinson’s, the Norwegian Parkinson’s Research Fund, the Norwegian Parkinson’s Association, and Haukeland University, signaling a strong collaboration network for clinical trial management, patient recruitment, and biomarker services.

Licensing Opportunities The novel dual MOA targeting PGC-1a and TFEB across neuro and metabolic indications presents viable licensing or co development options with larger pharma players seeking new mechanisms and multi indication potential.

Lean Operations With a very small team, Endurance Bio can leverage external CROs, CDMOs, and specialty vendors for development, manufacturing, and data services, creating opportunities for partner solutions in clinical operations, regulatory support, and analytics.

Broad Indication Appeal The K MOA relevance across neuro, metabolic, and other disease areas supports a multi indication strategy and potential geographic expansion, making it attractive for partners pursuing broad asset utility and risk diversification.